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Recent evidence on the association of lymphangiogenic
growth factors with intralymphatic growth and metastasis
of cancers (1–4) has raised hopes that lymphatic vessels
could be used as an additional target for tumor therapy.
Cancer cells spread within the body by direct invasion to
surrounding tissues, spreading to body cavities, invasion
into the blood vascular system (hematogenous metastasis),
as well as spread via the lymphatic system (lymphatic me-
tastasis). Regional lymph node dissemination is the first step
in the metastasis of several common cancers and correlates
highly to the prognosis of the disease. The lymph nodes
that are involved in draining tissue fluid from the tumor
area are called sentinel nodes, and diagnostic measures are
in place to find these nodes and to remove them in cases of
suspected metastasis. However, in spite of its clinical rele-
vance, little is known about the mechanisms leading to me-
tastasis via the bloodstream or via the lymphatics.
 
Until recently, the lymphatic vessels have received much
less attention than blood vessels, despite their importance in
medicine. Lymphatic vessels collect protein-rich fluid and
white blood cells from the interstitial space of most tissues
and transport them as a whitish opaque fluid, the lymph,
into the blood circulation. Small lymphatic vessels coalesce
into larger vessels, which drain the lymph through the tho-
racic duct into large veins in the neck region. Lymph nodes
serve as filtering stations along the lymphatic vessels and
lymph movement is propelled by the contraction of smooth
muscles surrounding collecting lymphatic vessels and by
 
bodily movements, the direction of flow being secured
by valves as it is in veins. The lymphatic capillaries are lined
by endothelial cells, which have distinct junctions with fre-
quent large interendothelial gaps. The lymphatic capillaries
also lack a continuous basement membrane, and are devoid
of pericytes. Anchoring filaments connect the abluminal
surfaces of lymphatic endothelial cells to the perivascular
extracellular matrix and pull to maintain vessel patency in
the presence of tissue edema. The absence or obstruction of
lymphatic vessels, which is usually the result of an infection,
surgery, or radiotherapy and in rare cases, a genetic defect,
causes accumulation of a protein-rich fluid in tissues,
lymphedema. The lymphatic system is also critical in fat ab-
sorption from the gut and in immune responses. Bacteria,
viruses, and other foreign materials are taken up by the lym-
phatic vessels and transported to the lymph nodes, where
the foreign material is presented to immune cells and where
dendritic cells traverse via the lymphatics. There has been
slow progress in the understanding of and ability to manip-
ulate the lymphatic vessels during the past several decades.
 
Two members of the vascular endothelial growth factor
(VEGF) family, VEGF-C and VEGF-D, have been associ-
ated with lymphangiogenesis (5–7). These factors are ligands
for the lymphatic endothelial VEGF receptor 3 (VEGFR-3),
but upon proteolytic processing they gain the ability to bind
and activate also VEGFR-2 (8, 9). VEGFR-2 is the main
angiogenic signal transducer for VEGF while VEGFR-3 is
specific for VEGF-C and VEGF-D and necessary and suffi-
cient for lymphangiogenic signaling (for a review, see refer-
ence 10). However, both VEGF-C and VEGF-D can also
be angiogenic (11, 12), provided they undergo enough pro-
teolytic processing, and that their receptors are expressed on
the target blood vessels. In normal adult tissues VEGFR-3 is
expressed almost exclusively in lymphatic endothelia, but for
example in tumors it is also expressed in endothelial cells of
blood vessels, where it is thought to contribute to tumor an-
giogenesis (13, 14). VEGF-C can also enhance blood vascu-
lar permeability via VEGFR-2 (15).
VEGF-C expression has been detected in about half of
human cancers analyzed (16). In breast cancer VEGF-C
expression seems to correlate with lymph node positive tu-
mors whereas VEGF-D may be expressed predominantly
in inflammatory breast carcinoma (17). Increased VEGF-C
levels have also been reported to correlate with lymph
node metastases in thyroid, prostate, gastric, colorectal, and
lung cancers (18–23). In one study VEGF-C expression
correlated with lymphatic vessel density, but not metastasis
(24). Such highly provocative clinical correlations between
lymphangiogenic growth factor expression and metastasis
should be extended to larger sets of patients and tumor
types. In addition, animal models are needed to elucidate
the mechanisms by which such correlation occurs. Clarijs
et al. (25) attributed the strictly hematogenous metastasis of
primary uveal melanomas to the absence of lymphatics in
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and around the tumor. Their data suggests that, although
VEGFR-3 is expressed in tumor blood vessels, VEGF-C
expression is not sufficient to induce lymphangiogenesis
from preexisting blood vessels in human cancer. This is
consistent with the conclusion of Kriehuber et al. (26) and
Makinen et al
 
.
 
 (27) that in adults differentiated lymphatic
and blood vascular endothelial cells form separate and stable
cell lineages. This reinforces the view that angiogenesis and
lymphangiogenesis represent coordinated but distinct pro-
cesses that can be separately targeted in human diseases.
Mandriota et al. (1) established transgenic mice in which
VEGF-C expression, driven by the rat insulin promoter, is
targeted to the 
 
 
 
-cells of the endocrine pancreas. The
transgenics developed an extensive network of lymphatic
vessels around the islets of Langerhans, which normally do
not have associated lymphatic vessels. The VEGF-C over-
expressing mice were crossed with mice that develop pan-
creatic 
 
 
 
-cell tumors, which are neither lymphangiogenic
nor metastatic. Double transgenic mice formed tumors
surrounded by well-developed lymphatics, which fre-
quently contained tumor cell masses of 
 
 
 
-cell origin.
These mice also frequently developed metastases in the
lymph nodes draining the pancreas. Similarly, human
breast cancer cells expressing ectopic VEGF-C were re-
cently shown to induce lymphangiogenesis in and around
the orthotopically implanted tumors (2, 4) and to spread to
the regional lymph nodes more frequently than the control
cells (2). Stacker et al. (3) overexpressed VEGF-D in trans-
formed human kidney cell xenografts in mice and obtained
tumor lymphangiogenesis but also angiogenesis, probably
because of increased proteolytic processing of VEGF-D.
All groups used monoclonal antibodies against a lym-
phatic-specific hyaluronan receptor called LYVE-1 (28,
29) to demonstrate an increase of peritumoral lymph ves-
sels when they compared VEGF-C or VEGF-D overex-
pressing tumors to control tumors. Intratumoral lymphatic
vessels were also observed in the tumor xenografts, but not
in the transgenic tumors, which may be at least partially
explained by the trapping of vessels in between growing
tumor foci in the xenografts that start from an injected cell
suspension. Thus, tumor vascularization can be dissected
into pathways that preferentially activate angiogenesis
(driven by VEGF) and pathways that preferentially activate
lymphangiogenesis (driven by VEGF-C and VEGF-D;
Fig. 1), although there now is evidence that both processes
can occur simultaneously in response to certain growth
factors (unpublished data).
Although it seems evident that VEGF-C can induce
new lymphatic vessels as well as hyperplasia of preexisting
lymphatic vessels (5, 6), we need to understand more
about the relationship between VEGF-C and VEGF-D
expression and lymphatic metastasis and its possible mech-
anisms. For example, is it sufficient for preexisting lym-
phatic vessels to expand by circumferential growth or does
one need additional new vessels for the enhancement of
metastasis? Do lymphatic vessels penetrate into existing tu-
mors or are they just trapped in between expanding tumor
foci, which appears likely in experimental tumor xe-
Figure 1. Tumor lymphan-
giogenesis and its inhibition.
VEGF-C and VEGF-D pro-
duced by tumor cells or associ-
ated inflammatory cells induce
the growth of lymphatic vessels
in the tumor periphery. These
factors may also contribute to
angiogenesis induced by VEGF.
Tumor cells grow inside of the
lymphatic vessels, which pro-
vide a route for tumor metastasis.
Shown in the top part are vari-
ous approaches to inhibit tumor
lymphangiogenesis and lym-
phatic metastasis by blocking
VEGFR-3 signaling. 
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nografts? Does lymphatic sprouting occur into tumors, or
do lymphatics grow by peritumoral hyperplasia and by
vessel splitting and fusion? Are the intratumoral lymphatic
vessels seen in occasional tumors collapsed and nonfunc-
tional because of the high interstitial pressure in solid tu-
mors? Are all lymphatic endothelial cells derived from pre-
existing ones or is there contribution by some sort of
precursor cells (lymphangioblasts) similar to what has been
described for the blood vascular endothelium (hemangio-
blasts and endothelial precursor cells; for a review, see ref-
erence 30) and for avian embryonic tissues (31). Do the
blood vascular and lymphatic endothelia become irrevers-
ibly committed to their differentiated phenotypes, as sug-
gested by the recent data (26, 27), and at what stage in
their differentiation program does this occur? Does lym-
phangiogenesis follow tumor angiogenesis as it does in sev-
eral developmental processes, where VEGF-C may act as a
coupling factor between the two?
In human tumors, most of the lymphatic vessels occur
peritumorally (32), but detection of occasional intratu-
moral lymphatic vessels can have prognostic significance,
for example in melanomas of the skin (Michael Detmar,
personal communication). It is not known to what extent
tumor cell secreted factors are directly responsible for the
large lymphatics detected around the tumor and to what
extent for example inflammatory cells, such as macro-
phages contribute to lymphangiogenesis. VEGF-C is che-
motactic for macrophages (33) and readily induced by
proinflammatory cytokines (34, 35). The dilated and en-
gorged peritumoral lymphatics may function poorly be-
cause intralymphatic growth of tumor cells clogs such ves-
sels. Could this cause a backwash effect diverting invading
cells into the venous circulation?
The simplest explanation for the metastasis-enhancing
effects of VEGF-C and VEGF-D is that they eliminate one
rate-limiting step by increasing the surface contact area be-
tween the invading tumor cells and the hyperplastic lym-
phatic endothelium. However, VEGF-C could also facili-
tate metastasis by increasing vascular permeability, or by
changing the adhesive properties or cytokine or chemo-
kine expression patterns of the lymphatic endothelium. For
example, there is evidence that the lymphatic expression of
the secondary lymphoid tissue chemokine (SLC; reference
26) not only attracts dendritic cells, but also certain tumor
cells expressing the corresponding receptors (36). VEGF-C
and VEGF-D secreted by tumor cells could also have im-
portant effects on the tumor interstitial pressure. Both can
increase vascular leak, but not as efficiently as VEGF (15),
and a possible parallel increase in lymphangiogenesis could
alleviate this effect. The increased interstitial pressure
could be a major determinant of tumor cell seeding into
the blood vascular and lymphatic circulation, especially as
recent studies have shown that a significant proportion of
the surface of tumor blood vessels is covered by the tumor
cells (37, 38).
The switch on of tumor angiogenesis occurs at least par-
tially due to activation of matrix metalloproteases upon tu-
mor progression (39). Tumor or associated inflammatory
 
cell secreted proteases can also cleave VEGF-C and VEGF-D
and thus regulate their angiogenic versus lymphangio-
genic properties. Furthermore, at least some specific ge-
netic events in tumor progression correlate with lymphatic
metastasis and a lymphangiogenic switch mechanism could
operate upon such oncogenic insults. In a recent study
Cavallaro et al. (40) found that in transgenic mice deficient
Figure 2. Inhibition of tumor lymphangiogenesis by adenovirally en-
coded soluble VEGFR-3. MCF-7 breast carcinoma cells were stably
transfected with a VEGF-C expression plasmid (A and B) or an empty
vector (C) and 107 cells were injected into the mammary fad pads of ova-
riectomized SCID mice carrying slow-release estrogen pellets. The mice
were injected intravenously with 109 PFU of an adenovirus encoding sol-
uble VEGFR-3 (B) or control adenovirus (A and C). See reference 4 for
further details. 
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of the neural cell adhesion molecule, pancreatic tumors
show disaggregation and detachment of cells and disperse
cell clumps that can be found in blood and lymphatic ves-
sels and which metastasize to nearby lymph nodes. It would
be interesting to know if VEGF-C or VEGF-D are upreg-
ulated in such tumors.
Recent reports have indicated that at least newly formed
lymphatic vessels are dependent on molecular signals that
can be interrupted (41), and these findings form a basis for
the inhibition of lymphangiogenesis. In transgenic mice
with targeted expression of a soluble form of VEGFR-3 in
the skin, lymphatic vessels initially formed normally, but
the onset of transgene expression led to regression of lym-
phatic vessels in embryos and to mice that completely lack a
dermal lymphatic system (41). Such mice now serve as a
model for studies of for example skin tumor metastasis in
the absence of the lymphatic vessels. Furthermore, neutral-
izing antibodies against VEGF-D decreased the number of
lymphatic metastases of the VEGF-D producing tumors (3)
and soluble VEGFR-3 produced via an adenovirus vector
could inhibit tumor-associated lymphangiogenesis in a
transplantable human breast carcinoma model in SCID
mice (4; Fig. 2). Microhemorrhage and the subsequent col-
lapse of large tumor vessels was also reported in mice
injected with blocking monoclonal antibodies against
VEGFR-3 (42); thus, VEGFR-3 targeted therapy has the
possibility of destabilizing tumor blood vessels as well. It is
now essential to find out if such anti-lymphangiogenic
treatments have side effects on normal vascular function.
Besides the recently identified lymphatic endothelial cell
surface proteins, the lymphatic vessels are also likely to ex-
press other tissue- and even tumor-specific molecules.
Methods such as cDNA microarray analysis and phage dis-
play screening are being used to identify relevant markers
and use them for selective drug targeting to the lymphatic
vessels. Targeted imaging of lymphatic vessels could also be
possible in cancer patients. The current targeting technolo-
gies make it possible to develop almost any drug into a tar-
geted compound, thereby increasing the potency of the
drug at the intended target tissue, while reducing side ef-
fects elsewhere in the body (43, 44). An attractive possibil-
ity would also be to target anti-cancer drugs into the tumor
lymphatics and to specifically destroy peritumoral lymphatic
vessels, which could inhibit lymphatic metastasis. However,
we do not know yet whether lymphatic destruction would
further elevate the tumor interstitial pressure, which is a se-
vere problem for drug delivery into tumors and presumably
a risk factor for hematogenous metastasis (45, 46). One
consideration is that there could be a compensatory increase
of lymphangiogenic growth factor levels; at least VEGF-D
expression is regulated by cell–cell contacts (47).
For the discovery of drug targets in the lymphatic endo-
thelium, direct in vivo screening poses a problem, because
of the complexity of tissues within which the slender lym-
phatic vessels are embedded. An alternative is to isolate dif-
ferentiated lymphatic endothelial cells. Previous studies
have reported on the isolation of lymphatic endothelium
from lymphangiomas or from large mesenteric or thoracic
collecting ducts (for a review, see reference 48). In the
study of Kriehuber et al. (26) human skin was used for the
isolation of the endothelial cells derived from lymphatic
capillaries. This advance comes with the discovery of
the lymphatic endothelium-specific marker podoplanin, a
glomerular podocyte membrane mucoprotein (49). Both
podoplanin and LYVE-1 appear useful for the isolation of
lymphatic endothelial cells, although neither is absolutely
specific for these cells. Monoclonal antibodies against
VEGFR-3 also allowed the isolation of lymphatic endothe-
lial cells, which grew in culture in the presence of VEGF-C
and a suitable pericellular matrix without losing their differ-
entiated properties (27). Specific VEGFR-3 ligands could
induce cell migration and protected serum-deprived lym-
phatic endothelial cells from apoptosis. In normal adult tis-
sues VEGFR-3 antibodies are useful for the isolation of
lymphatic endothelial cells because the expression of
VEGFR-3 occurs almost exclusively by lymphatic vessels
(50). However, as already mentioned, in tumors it tends to
lose its specificity due to its upregulation in the angiogenic
blood vessels (13, 14).
There has been very little progress during the past several
decades in the ability to manipulate lymphatic vessel
growth or function. This may have changed now. The dis-
covery of the VEGF-C and VEGF-D growth factors for
lymphatic vessels as well as their receptor VEGFR-3 has
revived the lymphatic vascular field. Isolation and culture
of lymphatic endothelial cells is another milestone that fa-
cilitates the screening of useful drug targets in this system.
One important task for further research is to analyze the ef-
fects of various inhibitors of VEGFR-3 on tumor growth,
angiogenesis, interstitial pressure, lymphangiogenesis, and
metastasis (see Fig. 1). Another important one is to study
how to reconstitute lymphatic vessels of patients with
lymphedema after surgery or radiotherapy. This research
provides a unique opportunity for the development of new
and innovative medical technology for cancer and other
human diseases.
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